Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 20, 2017 07:00 ET | Source: Stemline Therapeutics

Stemline Therapeutics to Present at Upcoming Investor Conferences

NEW YORK, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
September 11, 2017 07:00 ET | Source: Stemline Therapeutics

Stemline Therapeutics Presents SL-801 Phase 1 Data at ESMO 2017

NEW YORK, Sept. 11, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
September 08, 2017 07:30 ET | Source: Stemline Therapeutics

Stemline Therapeutics to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

NEW YORK, Sept. 08, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
August 30, 2017 18:10 ET | Source: Stemline Therapeutics

Stemline Therapeutics to Present SL-801 Phase 1 Data at Upcoming ESMO Congress

NEW YORK, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
August 14, 2017 07:30 ET | Source: Stemline Therapeutics

Stemline Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference

NEW YORK, Aug. 14, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
August 08, 2017 07:00 ET | Source: Stemline Therapeutics

Stemline Therapeutics Reports Second Quarter 2017 Financial Results

NEW YORK, Aug. 08, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
June 23, 2017 09:36 ET | Source: Stemline Therapeutics

Stemline Therapeutics Presents SL-401 Updated Stage 1 and 2 Data from Ongoing Pivotal Trial in BPDCN and Safety Experience Across Multiple Indications, Today at EHA

NEW YORK, June 23, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers,...
June 06, 2017 07:30 ET | Source: Stemline Therapeutics

Stemline Therapeutics to Present at the Jefferies 2017 Healthcare Conference

NEW YORK, June 06, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet...
May 18, 2017 07:30 ET | Source: Stemline Therapeutics

Stemline Therapeutics to Present SL-401 Updated Data from Stage 1 and 2 of Ongoing Pivotal Phase 2 BPDCN Trial at Upcoming European Hematology Association (EHA) Meeting

NEW YORK, May 18, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet...
May 10, 2017 17:12 ET | Source: Stemline Therapeutics

Stemline Therapeutics Reports First Quarter 2017 Financial Results

NEW YORK, May 10, 2017 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology indications of unmet...